Metformin and lipodystrophy

NEW YORK, 26 July (Praxis Press) The human immunodeficiency virus (HIV) lipodystrophy syndrome is characterized by fat redistribution and insulin resistance; this syndrome is particularly common among patients receiving combined antiretroviral therapy. Hadigan and colleagues studied the safety and efficacy of metformin in patients with the HIV lipodystrophy syndrome. Low-dose metformin treatment decreased body mass index and abdominal fat, improved hyperinsulinemia, and lowered diastolic blood p

The Scientist Staff
Jul 26, 2000

NEW YORK, 26 July (Praxis Press) The human immunodeficiency virus (HIV) lipodystrophy syndrome is characterized by fat redistribution and insulin resistance; this syndrome is particularly common among patients receiving combined antiretroviral therapy. Hadigan and colleagues studied the safety and efficacy of metformin in patients with the HIV lipodystrophy syndrome. Low-dose metformin treatment decreased body mass index and abdominal fat, improved hyperinsulinemia, and lowered diastolic blood pressure. No serious adverse effects were noted; mild diarrhea was the most common minor adverse effect. Low-dose metformin is an effective and well-tolerated treatment for HIV lipodystrophy.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?